Reply to the letter to the editor 'Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting' by van der Galiën et al.

Maurer, M J

Reply to the letter to the editor 'Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting' by van der Galiën et al. [electronic resource] - Annals of oncology : official journal of the European Society for Medical Oncology 01 2019 - 153 p. digital

Publication Type: Letter; Research Support, Non-U.S. Gov't; Comment

1569-8041

10.1093/annonc/mdy492 doi


Humans
Lymphoma, Large B-Cell, Diffuse
Progression-Free Survival
Randomized Controlled Trials as Topic
Rituximab